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Background: Patients with bone metastases from non-small cell lung 
cancer (NSCLC) may experience potentially disabling skeletal-related 
events (SREs) such as pathologic fracture, spinal cord compression, 
bone pain requiring palliative radiotherapy, orthopedic surgery, and 
hypercalcemia of malignancy. Most patients with bone metastases from 
NSCLC experience at least 1 SRE. Over a patient’s lifetime, multiple 
SREs may occur. Therefore, prevention of SREs is important to prevent 
the loss of patients’ functional independence. Zoledronic acid (ZOL) 
can reduce the risk of SREs in patients with bone metastases from solid 
tumors. We evaluated whether ZOL can reduce the burden of skeletal 
morbidity to patients with NSCLC using data from a large, randomized, 
placebo-controlled trial in patients with bone metastases from NSCLC 
or other solid tumors.
Methods: A retrospective evaluation of SREs was performed on 
patients with NSCLC who were randomized to treatment with either 
ZOL or placebo for up to 21 months (n = 378). All patients received 
concomitant antineoplastic therapy. Skeletal morbidity in the ﬁrst 6 
months on study was analyzed using a robust, survival-adjusted cumu-
lative mean function. 
Results: Patient demographics and baseline disease characteristics 
were similar between groups. The mean time from diagnosis of bone 
metastases to study entry was approximately 4 months, and approxi-
mately 70% of patients experienced an SRE before study entry. An 
evaluation of the ﬁrst 6 months of this study showed that in the placebo 
group, approximately 50% of patients experienced a ﬁrst on-study 
SRE (Figure 1), approximately 20% of whom went on to experience a 
second SRE. Moreover, some patients experienced a third event within 
this time period. Zoledronic acid not only reduced the incidence of ﬁrst 
on-study SREs, but also reduced the incidence of subsequent events in 
patients with NSCLC. Although this study was not statistically powered 
to evaluate differences for this endpoint, there was a clearly reduced 
rate of events for ZOL compared with placebo. 
Conclusions: The results of these analyses show that within a 6-month 
treatment period, ZOL reduced the incidence of a ﬁrst and subsequent 
SRE compared with placebo in patients with bone metastases from 
NSCLC. These analyses illustrate the fact that ZOL reduces skeletal 
morbidity and may therefore preserve quality of life and functional 
independence in patients with bone metastases from NSCLC.
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Background: Polo-like kinase 1 (Plk1), a key regulator of cell cycle 
progression and accurate spindle assembly, represents an attractive 
target for cancer drug development as it is highly expressed in malig-
nant cells and serves as a prognostic marker in certain human cancer 
types. We have previously shown that BI 2536, a potent and selective 
small-molecule inhibitor of Plk1, induces a characteristic mitotic arrest 
phenotype (“Polo-arrest”) and subsequent apoptosis in human cancer 
cells and is highly efﬁcacious in nude mouse xenograft models of 
human cancer at well-tolerated doses. BI 2536, the ﬁrst speciﬁc Plk1 
inhibitor in clinical development, has demonstrated encouraging results 
in phase I trials. This study was designed to examine the efﬁcacy of BI 
2536 in various models of NSCLC in vivo. 
Methods: The human NSCLC cell lines NCI-H460, NCI-H520TC, 
Calu-6 and A549 were used to evaluate the anti-tumor effects of BI 
2536. Cell proliferation in vitro was assessed using Alamar Blue 
assays. For in vivo studies, nude mice bearing subcutaneous human 
tumor xenografts were treated intravenously with 40 or 50 mg/kg of BI 
2536 given i.v. once or twice weekly for 2 to 7 weeks; control animals 
were injected with vehicle only. To assess the therapeutic potential of 
BI 2536 in combination with established chemotherapeutic agents, 
docetaxel (15 mg/kg once weekly i.v.), cisplatin (5 mg/kg once weekly 
i.p.) or pemetrexed (150 mg/kg i.p. on 5 consecutive days) were admin-
istered together with BI 2536. Efﬁcacy was determined by measuring 
tumor volumes and tolerability of treatment was assessed by determin-
ing clinical signs and body weight 3 times a week.
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Results: BI 2536 potently inhibited proliferation of NSCLC cell lines 
with EC50 values of 8 - 14 nM. The compound showed good anti-tu-
mor activity in vivo in all 4 NSCLC xenograft models tested with T/C 
(“treated/control”) values of 1% (Calu-6), 14% (A549), 21% (NCI-
H460), and 41% (NCI-H520TC) at doses that were well tolerated. Im-
munohistochemical analysis of NCI-H460 tumors excised from treated 
animals as well as near-infrared optical imaging using Cy5.5-coupled 
annexin V demonstrated mitotic arrest and induction of apoptosis in 
vivo. Combination therapy with established chemotherapeutic agents 
(cisplatin, docetaxel or pemetrexed) resulted in improved efﬁcacy in 
the absence of additional toxicity. 
Conclusion: BI 2536 is a potent inhibitor of NSCLC cell prolifera-
tion in vitro and shows efﬁcacy in multiple human NSCLC xenograft 
models at well-tolerated doses. Combination therapy with BI 2536 and 
established chemotherapeutic agents is well tolerated and results in 
improved efﬁcacy compared to single-agent treatment. 
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Background: ING genes (Inhibitor of Growth, ING1-5) are candidate 
tumor suppressor genes which have been recently identiﬁed and charac-
terized. Whereas ING1 expression has been shown to be down-regulat-
ed in several tumor types through a yet unknown mechanism (mutation 
of the gene is a rare event), few data have been reported regarding the 
status of other members of the family. ING2 is involved in tumor sup-
pression pathways such as apoptosis and senescence. It is a chromatin 
associated protein, a nuclear phosphoinositide receptor which interacts 
with trimethylated H3 on lysine 4 and can regulate p53 transcriptional 
activity by enhancing its acetylation to modulate cellular response to 
genotoxic stress. ING2 status in human tumors is still unknown (one 
study reported the reduced expression of ING2 in melanoma) and its 
role and regulation in carcinogenesis are poorly understood.
Methods: We investigated the involvement of ING2 in human lung 
tumors by analyzing ING2 protein expression on tumors and their 
related normal tissues (this study was done on samples from the tumor 
bank (CRB, Grenoble) and with tumor tissue micro-arrays. Immunohis-
tochemical analysis was performed on 75 formalin ﬁxed tumor tissues 
and normal counterpart using speciﬁc ING2 polyclonal antibody KMP1 
(kindly provided by Dr. C. Harris) dilution 1/100. Score of immunos-
taining (0-300) was established by multiplicating the percentage of 
stained cells (0-100) by intensity (1-3). Cut-off of score for discrimi-
nating positive from low expression and negative was determined by 
the mean level of expression on normal alveolar cells taken as internal 
control (mean 120): score of 0 to 50 considered as negative; 50 to 
120 as low and >120 as positive. mRNA were extracted by Trizol and 
analyzed by RT-PCR.
Results: A strong and mainly (but not exclusively) nuclear staining of 
ING2 was detected in normal lung tissues, mostly in Type II pneu-
mocytes. In non-small cell lung cancers, a loss or low level of ING2 
expression was observed in 75 % (27/36) adenocarcinoma and 82 % 
(32/39) squamous cell carcinoma as compared with normal lung. Fur-
thermore, in many cases, the ING2 nuclear staining was lost; whereas, 
the cytoplasmic staining was maintained. These results suggest that 
in tumor cells ING2 could be excluded from the nucleus. Analysis of 
mRNA expression by real-time PCR of 13 tumors and corresponding 
normal lung tissues showed a marked decrease of the mRNA in tumors. 
Since ING2 promoter contains several CpG islands, methylation of the 
promoter in these tumors is being investigated.
Conclusion: Taken together, these results suggest that ING2 could be 
inactivated in lung tumors either by downregulation at the mRNA level 
or exclusion of the protein from the nucleus. Further analysis of these 
tumors, especially their p53 status should help us to understand the role 
ING2 could play in lung carcinogenesis.
Rémy Pedeux was a recipient of a research grant from IASLC (2005-
2007).
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Background: Radiation dose escalation might improve local control 
in NSCLC, but is associated with increased toxicity. Consequently 
patients have to be selected carefully to prevent, both over- and under-
treatment. As part of a prospective clinical trial we reported that meta-
bolic responders and non-responders (EORTC-criteria) showed differ-
ent time trends in maximal SUV (standardized uptake value, SUVmax) 
of 18F-FDG on PET-scan. Moreover, metabolic responders showed an 
improved overall survival compared to non-responders (van Baard-
wijk et al., Radioth Oncol 2007). The aim of the current study was to 
investigate changes in plasma levels of cytokines and the association 
of these changes with SUVmax and the amount of toxicity during and 
after radiotherapy (RT), to further unravel underlying mechanisms.
Methods: From 21 patients included in the clinical trial, repeated 
plasma samples (n=67) were collected before RT, on day 7 and 14 
during RT and 70 days after RT. Levels of IL-1b, IL-5, IL-6, IL-8, 
IL-10, TNF-α, M30, M65, osteopontin and neopterin were assessed 
using ELISA’s. Unmeasurable levels were assumed to be zero. Levels 
of cytokines were associated with SUVmax of FDG-PET and toxicity 
score, according to CTCAE-criteria. Moreover, changes in levels of 
cytokines between the different time points during RT (day 0 versus 
day 7, day 7 versus day 14) were correlated with changes in SUVmax 
within the same time-interval. Results are expressed as mean ± SEM. 
Pearson correlation coefﬁcient and Mann Whitney U-test were used to 
analyze the data. 
Results: A large heterogeneity in evolution in cytokine levels during 
RT was observed between individual patients. It was shown that chang-
es in SUVmax correlated with changes in the level of IL-6, showing a 
